Cover Image
Market Research Report

Transmembrane Prolyl 4 Hydroxylase - Pipeline Review, H2 2019

Published by Global Markets Direct Product code 379068
Published Content info 70 Pages
Delivery time: 1-2 business days
Price
Back to Top
Transmembrane Prolyl 4 Hydroxylase - Pipeline Review, H2 2019
Published: December 27, 2019 Content info: 70 Pages
Description

Summary

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) pipeline Target constitutes close to 6 molecules. The latest report Transmembrane Prolyl 4 Hydroxylase - Pipeline Review, H2 2019, outlays comprehensive information on the Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Prolyl 4 hydroxylases (P4H) are iron- and 2-oxoglutamate-dependent dioxygenase enzymes and hypoxia-inducible transcription factor (HIF)-P4Hs play a critical role in the regulating oxygen homeostasis in the local tissues as well in the systemic circulation. This enzyme plays an important role in number of diseases including myocardial infarction, congestive heart failure, stroke, neurodegeneration, inflammatory disease, respiratory diseases, retinopathy and others. The molecules developed by companies in Pre-Registration, Phase III and Phase I stages are 2, 2 and 2 respectively. Report covers products from therapy areas Hematological Disorders and Toxicology which include indications Anemia in Chronic Kidney Disease (Renal Anemia), Anemia and Chemotherapy Induced Anemia.

Furthermore, this report also reviews key players involved in Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.)
  • The report reviews Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC2038TDB

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Overview
  • Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Companies Involved in Therapeutics Development
  • Bayer AG
  • FibroGen Inc
  • GlaxoSmithKline Plc
  • Japan Tobacco Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Taisho Pharmaceutical Holdings Co Ltd
  • Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Drug Profiles
  • daprodustat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DDO-3055 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • enarodustat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • molidustat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • roxadustat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TP-0463518 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Dormant Products
  • Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Discontinued Products
  • Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 02, 2019: FibroGen announces Roxadustat inclusion in China's National Reimbursement Drug List
  • Nov 29, 2019: JT Files New Drug Application of Enarodustat(JTZ-951),for the treatment of Anemia Associated with CKD in Japan
  • Nov 08, 2019: Roxadustat phase III program pooled analyses showed positive efficacy and no increased cardiovascular risk in patients with anemia from chronic kidney disease versus comparators
  • Nov 08, 2019: AstraZeneca reports positive Phase III data for roxadustat
  • Oct 30, 2019: AstraZeneca to present pivotal roxadustat phase III data at the American Society of Nephrology Kidney Week 2019
  • Oct 11, 2019: Roxadustat global phase 3 results for treatment of chronic kidney disease (CKD) Anemia to be Presented at American Society of Nephrology Kidney Week 2019
  • Sep 30, 2019: FibroGen receives one of China Pharmaceutical Industrys highest awards for clinical innovation for Roxadustat
  • Sep 26, 2019: FibroGen announces initiation of phase 2 clinical trial of Roxadustat for the treatment of anemia in cancer patients receiving chemotherapy
  • Sep 20, 2019: Roxadustat approved in Japan for the treatment of anemia associated with Chronic Kidney Disease in Dialysis Patients
  • Aug 23, 2019: GSK files daprodustat's first regulatory submission in Japan
  • Aug 21, 2019: Roxadustat Approved in China for Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis
  • Jul 24, 2019: The New England Journal of Medicine (NEJM) publishes Roxadustat China phase 3 results for the treatment of anemia in chronic kidney disease patients receiving dialysis
  • Jul 24, 2019: Roxadustat China phase 3 trial for treatment of anemia in chronic kidney disease patients not on dialysis published in the New England Journal of Medicine (NEJM)
  • Jul 12, 2019: Top-line Results of Phase 3 Clinical Studies of JTZ-951 (enarodustat), in Anemic Patients with Chronic Kidney Disease (Comparative Study) in Japan
  • May 09, 2019: FibroGen roxadustat announces positive topline results from pooled safety analyses of roxadustat global Phase 3 program
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Bayer AG, H2 2019
  • Pipeline by FibroGen Inc, H2 2019
  • Pipeline by GlaxoSmithKline Plc, H2 2019
  • Pipeline by Japan Tobacco Inc, H2 2019
  • Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
  • Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
Back to Top